ISTANBUL

The British biopharma giant GSK completed the acquisition of clinical-stage biopharmaceutical company Aiolos Bio for some $1.4 trillion, according to a press release on Thursday.

Aiolos Bio focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions, GSK said in a press release.

The acquisition of the firm includes "AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter phase II clinical development for the treatment of adult patients with asthma."

"AIO-001 could expand GSK's respiratory biologics portfolio to potentially reach the 40% of severe asthma patients with low T2 inflammation," it added.

According to a purchasing deal between companies, GSK will pay $1 billion for upfront payment and "up to $400 million in certain success-based regulatory milestone payments."